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Abstract
Background: The management of bisphosphonate related necrosis of the jaw has become clinical routine. While
approximately two thirds of the lesions are in the mandible, one third is located in the maxilla. In 40–50 % of
maxillary necrosis the maxillary sinus is involved, leading to maxillary sinusitis and oro-antral communications.
Methods: This retrospective single center study includes all patients with diagnosis of BP-ONJ of the maxilla and
concomitant maxillary sinusitis. The information collected includes age, gender, primary disease,
bisphosphonate intake, involving type of bisphosphonate, route of administration and duration of BP treatment
previous to surgical treatment and treatment outcome.
Results: A total of 12 patients fulfill the criteria of the diagnosis of maxillary sinusitis associated to maxillary necrosis, of
which 6 Patients showed purulent sinusitis. All patients underwent surgical treatment with complete resection of
the affected bone and a multilayer wound closure. A recurrence appeared in one patient with open bone and no
sign of sinusitis and was treated conservatively.
Conclusions: Purulent maxillary Sinusitis is a common complication of bisphosphonate-related necrosis of the
maxilla. The surgical technique described can be suggested for the treatment of these patients.
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Background
Since its first description in 2003, reports of bisphos-
phonate related osteonecrosis of the jaw (BP-ONJ) ac-
cumulate. With the ability to reduce bone turnover
through selective inhibition of osteoclasts, Bisphospho-
nates are used widespread in treatment of osteoporosis
and bony metastases of malignant diseases. They are
administered orally or intravenously, whereat the bio-
availability of oral bisphosphonates is below 1 % [1].
Once circulating in the blood, 70 % are covalently
bound to hydroxyapatite in bony tissues, the remainder
is secreted via the kidneys. BPs bound to the bone are
biologically inert, however, when absorbed by osteo-
clasts they lead to concentration dependent apoptosis
via inhibition of Farnesyl-Pyrophosphate-synthase [2].
Being integrated only during bone turnover, concentra-
tion is suspected to be higher in areas of high turnover
such as the alveolar processes [3]. Due to local factors
like chewing forces, oral bacteria, the periodontal gap
and a thin mucosa, the alveolar bone necessitates an el-
evated osteoclast-dependent bone turnover to maintain
integrity [4]. When osteoclasts are diminished by a high
local concentration of BPs, the bone is not capable to
react to these local factors what may end in necrosis
[5]. The prominent role of osteoclast inhibition in the
pathogenesis of BP-ONJ is underlined by recent reports
of osteonecrosis of the jaw following the treatment with
Denosumab, a selective antibody against RANK-L and
thus potent inhibitor of osteoclasts and its precursors,
which have a similar incidence like BP-ONJ after the
treatment with Zoledronate (ZOL), the BP with the
highest antiresorptive potency [6].
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The incidence of BP-ONJ is dependent on bisphos-
phonate type, route of administration and cumulative
dose, underlying disease, gender, co-medication and
oral health. It is lowest for oral treatment of primary
osteoporosis (0.05-0.2 %) and highest for intravenous
treatment of malignant diseases with bone metastases,
intravenous administration of ZOL and additional treat-
ment with inhibitors of angiogenesis or tyrosine-kinase
(up to 20.5 %) [7].
Treatment suggestions of BP-ONJ differ. In the 2014
update on Medication related osteonecrosis of the jaws
the American Association of Oral and Maxillofacial
Surgeons (AAOMS) recommends surgical debridement
or resection only in stage 2 and 3. Their approach has
the major treatment goals to enable continued onco-
logical therapy and preserve quality of life [8]. However,
the favored treatment with antibacterial mouth rinse
and antibiotic therapy only leads to freedom of symp-
toms in 53 % of the patients [9]. After promising results
of a surgical approach, that can lead to a closed oral
mucosa and absence of inflammation signs in 80-100 % of
the cases, other national associations favor a complete
necrosectomy with primary wound closure when the pa-
tients general condition allows it [10].
Roughly two thirds of the lesions occur in the man-
dible, only one third arises in the maxilla. While a pleth-
ora of articles present different perspectives of BP-ONJ,
only few studies explicitly highlight the manifestation in
the maxilla and only a case series of three patients exists
for a defined treatment regime [11–15].
The aim of this study was to review our cases with
maxillary BP-ONJ and concomitant sinusitis and to
introduce a technique for their management.
Method
This retrospective study includes all the patients with
the diagnosis of bisphosphonates-related osteonecrosis
of the maxilla and maxillary sinusitis that were operated
in our department between 2007 and 2011. Patients with-
out maxillary sinusitis, without a diagnosis consistent with
BP-ONJ or with history of radiation therapy to the jaws
were excluded. Data was collected using the hospital infor-
mation system.
All patients underwent surgery in general anesthesia
after two days of preoperative intravenous antibiotic
therapy with penicillin and metronidazole. Microbio-
logical samples are taken at the time of initial contact
with the patient and at the time of surgery when puru-
lent drainage was visible. After elevating a mucoperios-
teal flap using a crestal incision including areas of
exposed bone, all the affected bone was removed with
Luehr forceps and round burrs. Teeth in contact with
the affected bone were removed, sharp bony edges
rounded. After removal of the necrotic bone and thus
opening of the maxillary sinus, polypoid mucosa was
removed and the sinus was rinsed with iodine solution
and xylometazoline. The sinus was endoscopically
inspected. If the natural osteum was obstructed, it was
widened with Weil’s forceps. The wound was closed
using a multilayer technique previously described for
the mandible and adapted for the maxilla [16]. In this
technique, after slitting of the vestibular periosteum, its
mobile part is quilted under the palatinal mucosa with
absorbable backstitches. A second layer of absorbable
backstitches is used to align the wound edges to one level
and tighten the closure. A running suture brings the mu-
cosal edges together and closes the wound (Figs. 1 and 2).
Postoperatively, patients were fed via a nasogastric
feeding tube for five days. Intravenous antibiotic treat-
ment was continued until discharging the patient after
6 days. Until removal of sutures 18–21 days postopera-
tively, patients were asked to only eat soft food, avoid
blowing their noses and use xylometazoline nasal spray
and inhalation with natural brine and chlorhexidine
mouthwash frequently.
Postoperative controls were carried out for removal of
sutures and then every six months. When recall in our
unit was not feasible (e.g. distant place of residence)
controls were carried out by the local dentist.
Results
Twelve Patients met the inclusion criteria (10 female, 2
male) with a mean age of 67 years (range 55–82). Mean
follow up time was 25 months (range 19 – 58). Mean
duration of BP-treatment was 71 months (range 24–
144 months), five patients received Zoledronate (mean
50 months, range 36–70), three patients were treated
with Pamidronate (mean 117 months, 66–144 months),
two with Ibandronate (mean 72 months, 48 and 96)
and one with Alendronate (24 months) and Clodronate
(84 months) each. Except for Alendronate and Clodro-
nate, the route of administration was intravenously.
The underlying diseases were breast cancer and mul-
tiple myeloma in five patients, and lung cancer and
osteoporosis in one case respectively. BP-ONJ arose
after tooth extraction in 6 patients. In 3 patients peri-
odontitis was noted as initiating factor, which could not
be clearly defined in the remaining three patients.
All patients were clinically classified BP-ONJ stage 3
[8]. Nine patients showed open bone lesions in the re-
gion of the second premolar or the first molar of one
side of the maxilla, in two patients the incisor region
was also involved. One Patient had intact mucosa of
the toothless maxilla and no open bone intraorally but
a sequestrum at the floor of the sinus with a purulent
sinusitis (Fig. 3). In total, in six of the twelve patients
the maxillary sinus was filled with ichor. Regarding the
size of the defect three extensive defects with complete
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opening of the basal alveolar crest, seven large defects
ranging from 15–30 mm and two small defects ranging
von 5 to 15 mm were seen.
Eleven of twelve patients had an uneventful wound heal-
ing. One patient had a relapse of open bone 18 months
after the surgery. However, the sinus was obstructed with
a thick soft tissue scar. It was decided only to remove
bony edges and sequestra not to endanger the delineation
of the sinus. Two years later the patient showed up with
an abscess of the ipsilateral cheek that was incised. Short
time later she succumbed to the metastasizing breast
cancer.
In all cases it was noticeable, that the Schneiderian
membrane was easy to detach from the underlying bone.
Fig. 2 Clinical example of the necrosotomy and wound closure
Fig. 1 Schematic drawing of the technique
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Endoscopic examination revealed whitish reticular lines
of the sinus mucosa consistently (Fig. 4). Histology of
the mucosa and the underlying bone was taken in se-
lected cases and resulted in regionally circumscribed
necrotic and partially demineralized bone under a
broadened mucosa (Fig. 5). The antibiotic testing of the
microbiological samples revealed no resistances against
the antibiotic regimen used.
Discussion
BP-ONJ is a side effect of antiresorptive treatment with
growing importance that arises more frequently in the
mandible than in the maxilla. The difference in bone
architecture with its reduced blood supply might be an
explanation, on the other hand, saliva and food parti-
cles accumulate in the mandible and might support
local infections. Because of the good vascularization of
Fig. 3 Cone beam CT showing a sequestrum and sinusitis in a patient without intraoral bone exposure
Fig. 4 Remarkable whitish lines in the endoscopic view of an involved
maxillary sinus
Fig. 5 Histology of an antral wall showing regionally circumscribed
necrotic and partially demineralized bone under a broadened mucosa
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the maxilla, osteomyelitis is rare in contrast to the
mandible, where the thick cortical bone is nutritioned
as an endartery system. Due to expansion of the maxil-
lary sinus, the bony volume of the dorsal maxillary
alveolar crest is mostly small, just reaching the root api-
ces. Infections of the maxillary bone are likely to affect
the maxillary sinus. The maxillary sinus itself is lined
with a thin mucosa that early reacts to dental infections
[17]. When periodontal infections or dental extractions
lead to BP-ONJ of the dorsal maxilla, an involvement
of the maxillary sinus is not unlikely: 40–50 % of the
patients with a maxillary BP-ONJ show an ipsilateral
maxillary sinusitis [12] and oro-antral fistulas occur in
one third of the cases with maxillary BP-ONJ, and their
management is demanding [15].
Triggering factors for BP-ONJ are tooth extractions
and other dental surgical procedures, sharp bony edges
and pressure marks. Other regions than the jaws are
extremely rarely involved in Bisphosphonate-associated
osteonecrosis. Some authors mention cutaneous manifest-
ation such as dental sinus tracts [18], and only few case re-
ports with Bisphosphonate-associated osteonecrosis of the
external auditory canal (BPECO) are available [19]. The
similarity of thin soft tissue coverage of the bone may ex-
plain a pathogenesis by minor self-inflicted trauma by
regular aural toilet with cotton buds or fingers in the outer
ear. Also secondary osteomyelitis can arise after otitis,
mastoiditis or sinusitis and may lead to osteonecrosis.
Remarkably, the sinus mucosa in all patients of the
present study was altered. Similarly to the oral muco-
periosteum, which can be very easily detached from the
bone in patients treated with BPs, it could be removed
from the underlying sinus bone without significant
force. This supports the theory that soft tissue adjacent
to bone is more affected by BPs than soft tissue that is
not in connection with bone [20]. It is discussed that
BPs are released from the bone by osteoclasts and low
pH-values and then internalized by fibroblasts and epi-
thelial cells [21]. Zoledronate inhibits proliferation and
elevates apoptosis of these soft tissue cells, and inhibits
expression of type-1-collagen [22]. As the periosteal
membrane is connected to the bony surface by collage-
nous fibers, and type-1-collagen expression needs to be
increased in maxillary mucosa healing, inhibition of fi-
broblasts and epithelial cells might explain the easier
detachment of the periost and Schneiderian membrane
[23]. Because vascular remodeling and neovascular for-
mation is delayed, soft tissue regeneration may also be
impaired in patients with BP-ONJ [24].
Treatment suggestions of manifest BP-ONJ differ.
Whereas the first reports on management of BP-ONJ
preferred a conservative approach, recent publications
favor a surgical approach. While many authors describe
treatment results between 84 and 100 % of mucosal
healing after complete necrosectomy and thorough
wound closure [16, 25, 26] healing of the necrosis oc-
curs in only 25 % after strictly conservative measures
and 28–58 % after partial resections or debridement
without soft tissue closure [27, 28]. The more advanced
regimes also reflect the argument that in most patients
a continued treatment with BPs is necessary. This leads
to higher concentrations in the jawbones resulting in
even worse healing of bone and soft tissue wounds
when surgery is done at a subsequent date. However, in
its 2014 update of the position paper the AAOMS still
recommends management with antibacterial mouth
rinses and antibiotics in most patients [8]. In the ex-
perience of our group the conservative treatment of
maxillary sinusitis did not lead to healing but to puru-
lent discharge [13]. Persisting oro-antral communica-
tions can be covered with obturators, albeit ill-fitting
dentures my lead to new osteonecrosis [11].
The technique proposed is adapted from a report of
our group published in 2012 where five of the 21 le-
sions implicated the maxilla [16]. One of the patients in
this current paper with multiple myeloma and Zoledro-
nate treatment was already reported in the previous
paper. In contrast to the technique described by Gallego
et al. we tried not to use the pedicled buccal fat pad in the
first surgical intervention in order to have more options in
a possible later operation [14]. While the buccal fat pad
provides a mechanic protection and a rich vascularization
in the BRONJ site, in the technique used, the perios-
teum that is quilted under the palatal mucosa serves as
a second layer for a reliable wound closure and helps to
develop a thick scar that seals off the bone from the
oral flora.
Interestingly, one of our patients who had a purulent si-
nusitis with a 9 × 8 mm measuring sequestrum did not
show any exposed bone intra- or extraorally, and tooth
extractions in the right maxilla had been carried out
more than one year before. In the last years, the non-
exposed variant has led to a discussion concerning the
staging of BP-ONJ [29]. In most reports however, sites
with the absence of a clear mucosal breakdown were
declared as non-exposed BP-ONJ even though sinus
tracts or periodontitis lesions existed. To our best
knowledge a purulent maxillary sinusitis caused by a
BP-ONJ sequestrum with completely bland oral mucosa
has not been described before. As they may lead to
pansinusitis, and orbital or intracranial implication,
purulent sinusitis has the potential of life threatening
complications and need to be treated early [30]. In our
case low dose cone beam CT helped to assess the
sequestrum and a complete unilateral opacification of
the sinus, and the patient had no remaining symptoms
after sequester removal, sinus surgery, and meticulous
wound closure.
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Conclusions
Maxillary sinusitis and oro-antral communication associ-
ated to maxillary osteonecrosis is a severe complication
of BP therapy. Cone beam computer tomography and
endoscopy are helpful diagnostic and intraoperative
tools. In combination with antibiotic treatment, the
technique described can be suggested for the manage-
ment of BP-ONJ and concomitant maxillary sinusitis.
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